Back to Screener

Eupraxia Pharmaceuticals Inc. - Common Stock (EPRX)

NASDAQ Micro Cap

Healthcare › Pharmaceutical Preparations

$6.85
Market Cap: $244M
Data as of Dec 31, 2025

Price History

Feb 9, 2026 — Mar 27, 2026

Investment Snapshot

  • P/B of 2.98 — trading above book value
  • Piotroski F-Score 4/9 — moderate financial health
  • Loss-making — negative ROE of -47.0%

Eupraxia Pharmaceuticals Inc. - Common Stock (EPRX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $244 million . Key value metrics: P/B ratio 2.98, Piotroski F-Score 4 out of 9 (moderate financial health) .

Value Score

Key Metrics

P/E Ratio
2.98
EPS
$-1.08
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology. View more Healthcare stocks →

Eupraxia Pharmaceuticals Inc. - Common Stock — Fundamental Analysis Summary

On financial health, EPRX shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -47.0% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 8.74.

StockPik's composite Value Score for EPRX is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

EPRX shows earnings declining at 51%.

Top Value Stocks in Healthcare

Symbol Price P/E Score
CYRX $8.21 4.7 100
CRMD $6.70 3.6 100
CGEN $2.06 5.5 100
ABEO $4.82 4.5 100
BDMD $2.01 5.8 100
How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
EPRT
Next
EPSM